Chorong Yang
Research Subjects
Research Interests
Chorong Yang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Gihoon You
ABL Bio Inc
1 shared publication - Jungwoo Choi
ABL Bio Inc
1 shared publication - Juyeun Jeon
ABL Bio Inc
1 shared publication - Kyungjin Park
ABL Bio Inc
1 shared publication - Sang Hoon Lee
ABL Bio Inc
1 shared publication - Sora Kim
ABL Bio Inc
1 shared publication
Latest Publications
- Open Access
- 6 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2622746
Expanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety
Driven by the substantial limitations of first generation 4-1BB agonists urelumab and utomilumab, the field has shifted toward engineering next-generation molecules with improved therapeutic windows. This review provides a comprehensive analysis of this evolution, detailing how key molecular design strategies are used to restrict 4-1BB activation to the tumor microenvironment. We summarize available clinical data, highlighting that 4-1BB bispecific antibodies exhibit superior antitumor efficacy and more favorable safety profiles compared with their monospecific predecessors. Furthermore, we discuss strong rationale for combination strategies, emphasizing how 4-1BB signaling provides the crucial costimulatory signal necessary to sustain durable anti-tumor responses. In summary, this review elucidates the scientific basis of antibody engineering aimed at improving safety and tumor-selective activation of 4-1BB agonists and outlines future directions for optimizing their clinical application in cancer immunotherapy.
- 6 February 2026
- Published by Taylor & Francis in mAbs
- Vol. 18 (1) , 2622746
Open AccessExpanding the horizons of cancer therapy with next-generation 4-1BB agonists: a review of molecular and clinical strategies to maximize efficacy and ensure safety
Driven by the substantial limitations of first generation 4-1BB agonists urelumab and utomilumab, the field has shifted toward engineering next-generation molecules with improved therapeutic windows. This review provides a comprehensive analysis of this evolution, detailing how key molecular design strategies are used to restrict 4-1BB activation to the tumor microenvironment. We summarize available clinical data, highlighting that 4-1BB bispecific antibodies exhibit superior antitumor efficacy and more favorable safety profiles compared with their monospecific predecessors. Furthermore, we discuss strong rationale for combination strategies, emphasizing how 4-1BB signaling provides the crucial costimulatory signal necessary to sustain durable anti-tumor responses. In summary, this review elucidates the scientific basis of antibody engineering aimed at improving safety and tumor-selective activation of 4-1BB agonists and outlines future directions for optimizing their clinical application in cancer immunotherapy.